Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02535533 · ClinicalTrials.gov registry record · Phase 1
SLM + Axitinib for Clear Cell RCC
A Phase 1 study of Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC), sponsored by Mohammed Milhem.
- Completed
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
- 1
- Study location
NCT02535533 is a Phase 1 study of Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC) that has completed, run by Mohammed Milhem. The registered enrollment target is 46 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02535533, a Phase 1 study of Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC), has completed, sponsored by Mohammed Milhem.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial studies the side effects and best dose of L-selenomethionine when given together with axitinib in treating patients with clear cell renal cell carcinoma that has spread from the primary site (place where it started) to other places in the body and usually cannot be cured or controlled with treatment (advanced metastatic). L-selenomethionine may stop the growth of tumor cells by blocking the growth of new blood vessels necessary for tumor growth. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving L-selenomethionine together with axitinib may be a better treatment for advanced metastatic clear cell renal cell carcinoma.
Conditions Studied
Interventions
- DRUG Axitinib
- DRUG Selenomethionine (SLM)
Study Locations (1)
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2016-01 |
| Est. Completion | 2025-04-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02535533
The ClinicalTrials.gov registry entry for NCT02535533 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mohammed Milhem, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC) appearing as the primary indexed condition, and to 2 interventions - of which Axitinib is the first listed.
NCT02535533 reports 1 study location spanning 1 distinct geographic area - top geographies include Iowa.
Frequently Asked Questions
What is clinical trial NCT02535533 about?
NCT02535533 is a clinical study titled "SLM + Axitinib for Clear Cell RCC". This phase I trial studies the side effects and best dose of L-selenomethionine when given together with axitinib in treating patients with clear cell renal cell carcinoma that has spread from the primary site (place where it started) to other places in the body and usually cannot be cured or contro...
What is the current status of trial NCT02535533?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2016-01. Estimated completion is 2025-04-04.
What conditions does trial NCT02535533 study?
This clinical trial studies the following conditions: Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC).
What interventions are being tested in trial NCT02535533?
The interventions under investigation include: Axitinib (DRUG), Selenomethionine (SLM) (DRUG).
Who is sponsoring clinical trial NCT02535533?
This trial is sponsored by Mohammed Milhem, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02535533 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.